Pyxis Oncology (NASDAQ:PYXS) Price Target Raised to $19.00

Pyxis Oncology (NASDAQ:PYXS) had its target price upped by Wells Fargo & Company from $12.00 to $19.00 in a research note published on Wednesday, MarketBeat Ratings reports. The brokerage currently has an overweight rating on the stock.

Several other brokerages also recently weighed in on PYXS. Leerink Partners lowered their target price on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, July 2nd. Weiss Ratings cut shares of Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a research report on Tuesday, August 18th. Finally, Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.75.

Pyxis Oncology Trading Down 1.8%

Pyxis Oncology stock opened at $3.21 on Wednesday. The stock has a 50 day moving average of $3.03 and a two-hundred day moving average of $2.24. Pyxis Oncology has a twelve month low of $1.03 and a twelve month high of $5.55. The stock has a market capitalization of $267.75 million, a price-to-earnings ratio of -2.28 and a beta of 1.34.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Thursday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Equities analysts predict that Pyxis Oncology will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Several institutional investors have recently made changes to their positions in PYXS. Maia Wealth LLC purchased a new position in shares of Pyxis Oncology in the 4th quarter valued at about $25,000. Engineers Gate Manager LP acquired a new stake in shares of Pyxis Oncology in the fourth quarter valued at about $26,000. Fox Run Management L.L.C. purchased a new stake in Pyxis Oncology during the fourth quarter worth about $26,000. XTX Topco Ltd purchased a new stake in Pyxis Oncology during the second quarter worth about $40,000. Finally, LPL Financial LLC boosted its holdings in Pyxis Oncology by 150.7% during the fourth quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after buying an additional 21,100 shares in the last quarter. 39.07% of the stock is currently owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.